← Oncology Institute, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Total operating revenue | $187.5m |
$203.0m
+8.26%
|
$252.5m
+24.37%
|
$324.2m
+28.42%
|
$393.4m
+21.33%
|
$502.7m
+27.79%
|
$587.2m
+16.81%
|
|
| Selling, general and administrative expense | $41.9m | $83.4m | $119.7m | $113.9m | $107.8m | $105.6m | $111.4m | |
| Total operating expenses | $195.7m | $248.9m | $334.4m | $401.3m | $453.5m | $538.8m | $613.3m | |
| Loss from operations | ($684k) |
($45.9m)
-6605.67%
|
($82.0m)
-78.71%
|
($77.0m)
+6.02%
|
($60.1m)
+21.94%
|
($36.1m)
+39.98%
|
— | |
| Interest expense, net | — | $320k | $4.1m | $6.8m | $7.5m | $11.3m | $7.6m | |
| Total other non-operating expense | $6.6m | ($34.3m) | ($81.9m) | $6.1m | $4.5m | $24.7m | — | |
| Loss before provision for income taxes | ($430k) | ($11.6m) | ($91k) | ($83.1m) | ($64.7m) | ($60.7m) | — | |
| Income tax benefit | $11k | $671k | $243k | $36k | $0 | $131k | — | |
| Net loss | ($441k) | ($10.9m) | $152k | ($83.1m) | ($64.7m) | ($60.6m) | — | |
| Net loss attributable to common stockholders, basic | — | ($10.6m) | $68k | ($67.9m) | ($53.0m) | ($50.3m) | — | |
| Net loss attributable to common stockholders, diluted | — | ($10.6m) | ($17.0m) | ($67.9m) | ($53.0m) | ($50.3m) | — | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | ($0) | ($0) | $0 | ($1) | ($1) | ($1) | — | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | ($0) | ($0) | ($0) | ($1) | ($1) | ($1) | — | |
| Weighted-average number of shares outstanding, basic (in shares) | 59.1m | 66.2m | 72.8m | 73.7m | 75.0m | 92.4m | 101.0m | |
| Weighted-average number of shares outstanding, diluted (in shares) | 59.1m | 66.2m | 80.6m | 73.7m | 75.0m | 92.4m | 101.0m | |
| Direct costs | $150.6m | $162.2m | $200.4m | $264.7m | $339.4m | $426.3m | — | |
| Depreciation and amortization | $3.2m | $3.3m | $4.4m | $5.9m | $6.3m | $6.9m | $6.8m | |
| Change in fair value of derivative warrant liabilities | $0 | ($3.7m) | ($1.8m) | $286k | ($619k) | $247k | — | |
| Change in fair value of conversion option derivative liabilities | $0 | ($24.9m) | ($24.2m) | ($878k) | ($2.7m) | $12.2m | — | |
| Other, net | $6.3m | ($1.0m) | ($501k) | $704k | $365k | $925k | — |